Related Experiment Videos
Selective modulation of 5-fluorouracil action in patients with colorectal carcinoma
Abstract:
Attempts to modulate by normal metabolites the intracellular metabolism of 5-fluorouracil (FU) via the ribonucleotide pathway leading to increased incorporation of the drug into RNA have been shown to potentiate host toxicity but not the therapeutic efficacy of this agent in preclinical model systems and in patients with advanced colorectal carcinomas. Recent advances aimed at the modulation of FU metabolism by CF via the deoxyribonucleotide pathway leading to prolonged inhibition of dTMPS activity indicates that the therapeutic efficacy of FU can be enhanced significantly in patients with advanced colorectal carcinoma. Pharmacokinetic studies of FU and CF revealed large intrasubject variations. In this presentation, rationale and the results of approaches taken at the preclinical and clinical levels in an attempt to selectively modulate the therapeutic efficacy of fluoropyrimidine will be discussed. This includes the importance of integration of information concerning pharmacokinetics and cellular metabolism in the design of optimal combination chemotherapy of FU with metabolic modulators.
Insights
Modulating 5-fluorouracil (FU) metabolism via the deoxyribonucleotide pathway enhances its efficacy in colorectal cancer. Integrating pharmacokinetic and metabolic data is crucial for optimizing FU combination chemotherapy.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Attempts to enhance 5-fluorouracil (FU) efficacy by modulating its ribonucleotide pathway increased toxicity without improving therapeutic outcomes in colorectal cancer.
- Modulation of FU metabolism via the deoxyribonucleotide pathway, specifically through inhibition of thymidylate synthase (dTMPS), shows promise for enhancing therapeutic efficacy.
Purpose of the Study:
- To discuss the rationale and results of preclinical and clinical approaches to selectively modulate fluoropyrimidine efficacy.
- To highlight the importance of integrating pharmacokinetic and cellular metabolism data for designing optimal FU combination chemotherapy.
Main Methods:
- Review of preclinical and clinical studies investigating FU metabolism.
- Analysis of pharmacokinetic data for FU and its modulators.
- Exploration of cellular metabolism pathways, including ribonucleotide and deoxyribonucleotide pathways.
Main Results:
- Modulation via the ribonucleotide pathway potentiated toxicity but not efficacy.
- Modulation via the deoxyribonucleotide pathway significantly enhanced FU's therapeutic efficacy in advanced colorectal carcinoma.
- Significant intrasubject variations in FU and modulator pharmacokinetics were observed.
Conclusions:
- Selective modulation of FU metabolism, particularly via the deoxyribonucleotide pathway, can enhance therapeutic efficacy in colorectal cancer.
- Integration of pharmacokinetic and metabolic data is essential for developing effective FU-based combination therapies.